Equity Profile

SLNO

Soleno Therapeutics, Inc.

Health CareBiotechnology$2.8B

Mar23Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Soleno Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is essential for understanding the company's market traction and overall business expansion.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

SLNO Q2-2026 Earnings Preview

Context

Company Snapshot

Soleno Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases. Operating in the Health Care sector, its work is crucial as it addresses unmet medical needs, particularly in the treatment of metabolic disorders.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+1923.32%

Avg Stock Reaction

-0.32%

Last Quarter Recap

In the last quarter, Soleno reported an EPS of $0.59, which was below the expected $0.73, resulting in a 19.4% surprise. The stock saw a slight increase of 0.02% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Soleno's upcoming earnings are mixed, given the lack of analyst estimates and management guidance. Investors will be keenly watching for any signs of revenue growth or profitability.

Bull Case

If Soleno can demonstrate strong revenue growth and better-than-expected EPS, it could signal a turnaround and boost investor confidence.

Bear Case

Conversely, if the company fails to meet expectations again, it may raise concerns about its long-term viability and lead to a decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

The EPS figure will be critical in assessing the company's profitability and could heavily influence investor sentiment.

What is the revenue growth rate compared to last quarter?

Understanding revenue growth is essential for evaluating the company's market performance and future prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Soleno's potential for recovery, given its recent history of beating EPS estimates despite lower revenue.

Supporting Evidence

The company has a 63% EPS beat rate historically, indicating potential for positive surprises.

Options pricing suggests a larger move than historical averages, indicating heightened expectations.

The recent stock performance following earnings has shown resilience despite mixed results.

Key Risk

If the company reports an EPS above $0.60, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is under scrutiny as investors look for signs of recovery after a disappointing last report.

Bull Confirmed If

A revenue growth rate of over 15% compared to the previous quarter would confirm the bull case.

Bear Confirmed If

If the EPS falls below $0.50, it would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±5.47%

Historical Avg

±2.0%

Pricing rich

The options market is pricing in a significant move of about 5.5%, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±5.5% while SLNO has averaged ±2.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

81.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Soleno beats expectations, history suggests the stock could rise around 0.02% on the first day, confirming a positive trend.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction, reflecting investor caution.

Miss

A miss could lead to a decline, with history suggesting an average drop of around 0.20% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product developments or clinical trials.
2Management's outlook on revenue growth for the upcoming quarters.
3Details on cost management strategies and their impact on profitability.
4Insights into market demand for Soleno's therapies.
5Any commentary on competitive landscape and positioning.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

PDD Holdings Inc.

Company Snapshot

Soleno Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is essential for understanding the company's market traction and overall business expansion.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

SLNO Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+1923.32%

Avg Stock Reaction

-0.32%

Last Quarter Recap

In the last quarter, Soleno reported an EPS of $0.59, which was below the expected $0.73, resulting in a 19.4% surprise. The stock saw a slight increase of 0.02% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Soleno can demonstrate strong revenue growth and better-than-expected EPS, it could signal a turnaround and boost investor confidence.

Bear Case

Conversely, if the company fails to meet expectations again, it may raise concerns about its long-term viability and lead to a decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

The EPS figure will be critical in assessing the company's profitability and could heavily influence investor sentiment.

What is the revenue growth rate compared to last quarter?

Understanding revenue growth is essential for evaluating the company's market performance and future prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Soleno's potential for recovery, given its recent history of beating EPS estimates despite lower revenue.

Supporting Evidence

The company has a 63% EPS beat rate historically, indicating potential for positive surprises.

Options pricing suggests a larger move than historical averages, indicating heightened expectations.

The recent stock performance following earnings has shown resilience despite mixed results.

Key Risk

If the company reports an EPS above $0.60, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is under scrutiny as investors look for signs of recovery after a disappointing last report.

Bull Confirmed If

A revenue growth rate of over 15% compared to the previous quarter would confirm the bull case.

Bear Confirmed If

If the EPS falls below $0.50, it would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±5.47%

Historical Avg

±2.0%

Pricing rich

The options market is pricing in a significant move of about 5.5%, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±5.5% while SLNO has averaged ±2.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

81.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Soleno beats expectations, history suggests the stock could rise around 0.02% on the first day, confirming a positive trend.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction, reflecting investor caution.

Miss

A miss could lead to a decline, with history suggesting an average drop of around 0.20% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product developments or clinical trials.
2Management's outlook on revenue growth for the upcoming quarters.
3Details on cost management strategies and their impact on profitability.
4Insights into market demand for Soleno's therapies.
5Any commentary on competitive landscape and positioning.